Company · CIK 0001070081 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
PTC THERAPEUTICS, INC. · PTCT
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 SForm 4 → | Sep 18, 5:20 pm EDT | Michael SchmertzlerDirector | 20,000 | $67.49 | $1,349,728 | 1,296,594 | −1.52% | 10b5-1 |
| Sep 9, 2026 SForm 4 → | Sep 11, 5:20 pm EDT | Michael SchmertzlerDirector | 20,000 | $67.59 | $1,351,803 | 1,316,594 | −1.50% | 10b5-1 |
| Aug 26, 2026 SForm 4 → | Aug 28, 5:20 pm EDT | Michael SchmertzlerDirector | 25,000 | $72.26 | $1,806,509 | 1,336,594 | −1.84% | 10b5-1 |
| Aug 19, 2026 SForm 4 → | Aug 21, 5:20 pm EDT | Michael SchmertzlerDirector | 25,000 | $72.22 | $1,805,411 | 1,361,594 | −1.80% | 10b5-1 |
| Aug 17, 2026 SForm 4 → | Aug 19, 5:20 pm EDT | Mark Elliott BouldingEXEC. VP AND CLO | 2,813 | $72.57 | $204,127 | 105,272 | −2.60% | 10b5-1 |
| Aug 17, 2026 MForm 4 → | Aug 19, 5:20 pm EDT | Mark Elliott BouldingEXEC. VP AND CLO | 2,813 | $25.69 | $72,266 | 108,085 | — | 10b5-1 |
| Aug 4, 2026 SForm 4 → | Aug 6, 5:20 pm EDT | Matthew B. KleinCHIEF EXECUTIVE OFFICER, Director | 10,292 | $68.57 | $705,722 | 383,868 | −2.61% | 10b5-1 |
| Jul 28, 2026 AForm 4 → | Jul 30, 9:02 pm EDT | Hege Elisabeth Sollie-ZetlmayerDirector | 6,000 | — | — | 52,526 | — | |
| Jul 14, 2026 SForm 4 → | Jul 16, 5:20 pm EDT | Pierre GravierCHIEF FINANCIAL OFFICER | 3,494 | $80.35 | $280,743 | 83,986 | −3.99% | 10b5-1 |
| Jul 9, 2026 SForm 4 → | Jul 13, 5:20 pm EDT | Mary L. SmithDirector | 15,834 | $90.00 | $1,425,060 | 21,813 | −42.1% | 10b5-1 |
| Jul 9, 2026 MForm 4 → | Jul 13, 5:20 pm EDT | Mary L. SmithDirector | 15,834 | $42.95 | $680,070 | 27,647 | — | 10b5-1 |
| Jul 9, 2026 SForm 4 → | Jul 13, 5:20 pm EDT | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | 2,464 | $90.25 | $222,376 | 60,299 | −3.93% | 10b5-1 |
| Jul 9, 2026 MForm 4 → | Jul 13, 5:20 pm EDT | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | 2,464 | $46.54 | $114,675 | 62,763 | — | 10b5-1 |
| Jul 6, 2026 SForm 4 → | Jul 8, 5:20 pm EDT | Mark Elliott BouldingEXEC. VP AND CLO | 5,079 | $85.08 | $432,118 | 105,272 | −4.60% | 10b5-1 |
| Jul 6, 2026 MForm 4 → | Jul 8, 5:20 pm EDT | Mark Elliott BouldingEXEC. VP AND CLO | 5,079 | $43.36 | $220,243 | 108,085 | — | 10b5-1 |
| Jul 6, 2026 SForm 4 → | Jul 8, 5:20 pm EDT | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | 46,774 | $87.52 | $4,093,482 | 60,299 | −43.7% | 10b5-1 |
| Jul 6, 2026 MForm 4 → | Jul 8, 5:20 pm EDT | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | 46,774 | $38.86 | $1,817,844 | 84,912 | — | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 MForm 4 → | Aug 19, 5:20 pm EDT | Mark Elliott BouldingEXEC. VP AND CLO | 2,813 | — | — | 16,876 | — | 10b5-1 |
| Jul 28, 2026 AForm 4 → | Jul 30, 9:02 pm EDT | Hege Elisabeth Sollie-ZetlmayerDirector | 5,213 | — | — | 1,738 | — | |
| Jul 9, 2026 MForm 4 → | Jul 13, 5:20 pm EDT | Mary L. SmithDirector | 15,834 | — | — | 0 | — | 10b5-1 |
| Jul 9, 2026 MForm 4 → | Jul 13, 5:20 pm EDT | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | 2,464 | — | — | 45,036 | — | 10b5-1 |
| Jul 6, 2026 MForm 4 → | Jul 8, 5:20 pm EDT | Mark Elliott BouldingEXEC. VP AND CLO | 5,039 | — | — | 28,125 | — | 10b5-1 |
| Jul 6, 2026 MForm 4 → | Jul 8, 5:20 pm EDT | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | 46,774 | — | — | 9,063 | — | 10b5-1 |